Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Exclusions
Mortality
ICU
Hospitalization
Serious outcomes
Cases
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Vitamin C  COVID-19 treatment studies for Vitamin C  C19 studies: Vitamin C  Vitamin C   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
Outcomes in COVID-19 vitamin C studies
00.250.50.7511.251.51.752+Thomas (RCT)18%0.82 [0.53-1.27]recov. time48 (n)50 (n)CT​1Improvement, RR [CI]TreatmentControlZhao (PSM)72%0.28 [0.08-0.93]progression4/5512/55Tau​2 = 0.41; I​2 = 70.1%Early treatment46%0.54 [0.19-1.51]4/10312/10546% improvementKrishnan31%0.69 [0.47-0.92]death40/7952/73Improvement, RR [CI]TreatmentControlZhang (RCT)50%0.50 [0.20-1.50]death6/2711/29Patel29%0.71 [0.43-1.14]death22/9626/80Kumari (RCT)36%0.64 [0.26-1.55]death7/7511/75Darban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​1JamaliMog.. (RCT)0%1.00 [0.22-4.56]death3/303/30Gao86%0.14 [0.03-0.72]death1/465/30Hamidi-Ala.. (RCT)44%0.56 [0.20-1.51]death5/409/40CT​1Al Sulaiman (PSM)15%0.85 [0.61-1.12]death46/14259/142Mulhem-32%1.32 [1.07-1.62]death157/794359/2,425Gadhiya-1%1.01 [0.48-1.91]death19/5536/226Hakamifard (RCT)46%0.54 [0.14-2.08]ICU3/385/34CT​1Suna21%0.79 [0.44-1.41]death17/15324/170Li (PSM)-11%1.11 [0.79-1.54]death7/819/24Vishnuram54%0.46 [0.24-0.86]death164/8,63410/241Özgünay9%0.91 [0.63-1.30]death17/3275/128Tan25%0.75 [0.10-2.98]int./death1/4614/115CT​1Tau​2 = 0.07; I​2 = 56.6%Late treatment19%0.81 [0.67-0.99]517/10,305721/3,87219% improvementBehera10%0.90 [0.63-1.21]cases29/67157/305Improvement, RR [CI]TreatmentControlLouca0%1.00 [0.97-1.04]casesTau​2 = 0.00; I​2 = 0.0%PrEP0%1.00 [0.97-1.03]29/67157/3050% improvementAll studies14%0.86 [0.76-0.98]550/10,475890/4,28214% improvement21 vitamin C COVID-19 studiesc19vitaminc.com Sep 25, 20211 CT: study uses combined treatmentTau​2 = 0.03; I​2 = 54.7%; Z = 2.26Effect extraction pre-specifiedFavors vitamin CFavors control 00.250.50.7511.251.51.752+Thomas (RCT)18%0.82 [0.53-1.27]recov. time48 (n)50 (n)CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment18%0.82 [0.53-1.27]0/480/5018% improvementZhang (RCT)50%0.50 [0.20-1.50]death6/2711/29Improvement, RR [CI]TreatmentControlPatel29%0.71 [0.43-1.14]death22/9626/80Kumari (RCT)36%0.64 [0.26-1.55]death7/7511/75Darban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​1JamaliMog.. (RCT)0%1.00 [0.22-4.56]death3/303/30Gao86%0.14 [0.03-0.72]death1/465/30Hamidi-Ala.. (RCT)44%0.56 [0.20-1.51]death5/409/40CT​1Al Sulaiman (PSM)15%0.85 [0.61-1.12]death46/14259/142Hakamifard (RCT)46%0.54 [0.14-2.08]ICU3/385/34CT​1Tan25%0.75 [0.10-2.98]int./death1/4614/115CT​1Tau​2 = 0.00; I​2 = 0.0%Late treatment27%0.73 [0.59-0.91]96/550146/58527% improvementBehera10%0.90 [0.63-1.21]cases29/67157/305Improvement, RR [CI]TreatmentControlLouca0%1.00 [0.97-1.04]casesTau​2 = 0.00; I​2 = 0.0%PrEP0%1.00 [0.97-1.03]29/67157/3050% improvementAll studies9%0.91 [0.81-1.02]125/665303/9409% improvement13 vitamin C COVID-19 studies after exclusionsc19vitaminc.com Sep 25, 20211 CT: study uses combined treatmentTau​2 = 0.01; I​2 = 10.6%; Z = 1.70Effect extraction pre-specifiedFavors vitamin CFavors control 00.250.50.7511.251.51.752+Krishnan31%0.69 [0.47-0.92]40/7952/73Improvement, RR [CI]TreatmentControlZhang (RCT)50%0.50 [0.20-1.50]6/2711/29Patel29%0.71 [0.43-1.14]22/9626/80Kumari (RCT)36%0.64 [0.26-1.55]7/7511/75JamaliMog.. (RCT)0%1.00 [0.22-4.56]3/303/30Gao86%0.14 [0.03-0.72]1/465/30Hamidi-Ala.. (RCT)44%0.56 [0.20-1.51]5/409/40CT​1Al Sulaiman (PSM)15%0.85 [0.61-1.12]46/14259/142Mulhem-32%1.32 [1.07-1.62]157/794359/2,425Gadhiya-1%1.01 [0.48-1.91]19/5536/226Suna21%0.79 [0.44-1.41]17/15324/170Li (PSM)-11%1.11 [0.79-1.54]7/819/24Vishnuram54%0.46 [0.24-0.86]164/8,63410/241Özgünay9%0.91 [0.63-1.30]17/3275/128Tau​2 = 0.08; I​2 = 63.8%Late treatment18%0.82 [0.67-1.01]511/10,211699/3,71318% improvementAll studies18%0.82 [0.67-1.01]511/10,211699/3,71318% improvement14 vitamin C COVID-19 mortality resultsc19vitaminc.com Sep 25, 20211 CT: study uses combined treatmentTau​2 = 0.08; I​2 = 63.8%; Z = 1.90Favors vitamin CFavors control 00.250.50.7511.251.51.752+Darban (RCT)6%0.94 [0.84-1.06]10 (n)10 (n)CT​1Improvement, RR [CI]TreatmentControlHakamifard (RCT)46%0.54 [0.14-2.08]3/385/34CT​1Suna-2%1.02 [0.46-2.24]11/15312/170Tau​2 = 0.00; I​2 = 0.0%Late treatment6%0.94 [0.84-1.05]14/20117/2146% improvementAll studies6%0.94 [0.84-1.05]14/20117/2146% improvement3 vitamin C COVID-19 ICU resultsc19vitaminc.com Sep 25, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 1.10Favors vitamin CFavors control 00.250.50.7511.251.51.752+Kumari (RCT)24%0.76 [0.66-0.87]hosp. time75 (n)75 (n)Improvement, RR [CI]TreatmentControlJamaliMog.. (RCT)-31%1.31 [1.03-1.66]hosp. time30 (n)30 (n)Hamidi-Ala.. (RCT)38%0.62 [0.45-0.86]hosp. time40 (n)40 (n)CT​1Hakamifard (RCT)1%0.99 [0.91-1.07]hosp. time38 (n)34 (n)CT​1Tau​2 = 0.05; I​2 = 87.7%Late treatment10%0.90 [0.71-1.13]0/1830/17910% improvementAll studies10%0.90 [0.71-1.13]0/1830/17910% improvement4 vitamin C COVID-19 hospitalization resultsc19vitaminc.com Sep 25, 20211 CT: study uses combined treatmentTau​2 = 0.05; I​2 = 87.7%; Z = 0.91Favors vitamin CFavors control 00.250.50.7511.251.51.752+Zhao (PSM)72%0.28 [0.08-0.93]progression4/5512/55Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment72%0.28 [0.08-0.93]4/5512/5572% improvementKrishnan31%0.69 [0.47-0.92]death40/7952/73Improvement, RR [CI]TreatmentControlZhang (RCT)50%0.50 [0.20-1.50]death6/2711/29Patel29%0.71 [0.43-1.14]death22/9626/80Kumari (RCT)36%0.64 [0.26-1.55]death7/7511/75Darban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​1JamaliMog.. (RCT)0%1.00 [0.22-4.56]death3/303/30Gao86%0.14 [0.03-0.72]death1/465/30Hamidi-Ala.. (RCT)44%0.56 [0.20-1.51]death5/409/40CT​1Al Sulaiman (PSM)15%0.85 [0.61-1.12]death46/14259/142Mulhem-32%1.32 [1.07-1.62]death157/794359/2,425Gadhiya-1%1.01 [0.48-1.91]death19/5536/226Hakamifard (RCT)46%0.54 [0.14-2.08]ICU3/385/34CT​1Suna21%0.79 [0.44-1.41]death17/15324/170Li (PSM)-11%1.11 [0.79-1.54]death7/819/24Vishnuram54%0.46 [0.24-0.86]death164/8,63410/241Özgünay9%0.91 [0.63-1.30]death17/3275/128Tan25%0.75 [0.10-2.98]int./death1/4614/115CT​1Tau​2 = 0.07; I​2 = 56.6%Late treatment19%0.81 [0.67-0.99]517/10,305721/3,87219% improvementAll studies22%0.78 [0.64-0.96]521/10,360733/3,92722% improvement18 vitamin C COVID-19 serious outcomesc19vitaminc.com Sep 25, 20211 CT: study uses combined treatmentTau​2 = 0.08; I​2 = 59.4%; Z = 2.37Effect extraction pre-specifiedFavors vitamin CFavors control 00.250.50.7511.251.51.752+Behera10%0.90 [0.63-1.21]29/67157/305Improvement, RR [CI]TreatmentControlLouca0%1.00 [0.97-1.04]Tau​2 = 0.00; I​2 = 0.0%PrEP0%1.00 [0.97-1.03]29/67157/3050% improvementAll studies0%1.00 [0.97-1.03]29/67157/3050% improvement2 vitamin C COVID-19 case resultsc19vitaminc.com Sep 25, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.07Favors vitamin CFavors control 00.250.50.7511.251.51.752+Zhao (PSM)-8%1.08 [0.64-1.80]viral time55 (n)55 (n)Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment-8%1.08 [0.64-1.80]0/550/55-8% improvementAll studies-8%1.08 [0.64-1.80]0/550/55-8% improvement1 vitamin C COVID-19 viral clearance resultc19vitaminc.com Sep 25, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.28Favors vitamin CFavors control 00.250.50.7511.251.51.752+Thomas (RCT)18%0.82 [0.53-1.27]recov. time48 (n)50 (n)CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment18%0.82 [0.53-1.27]0/480/5018% improvementZhang (RCT)50%0.50 [0.20-1.50]death6/2711/29Improvement, RR [CI]TreatmentControlKumari (RCT)36%0.64 [0.26-1.55]death7/7511/75Darban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​1JamaliMog.. (RCT)0%1.00 [0.22-4.56]death3/303/30Hamidi-Ala.. (RCT)44%0.56 [0.20-1.51]death5/409/40CT​1Hakamifard (RCT)46%0.54 [0.14-2.08]ICU3/385/34CT​1Tau​2 = 0.00; I​2 = 0.0%Late treatment41%0.59 [0.38-0.93]26/22042/21841% improvementAll studies30%0.70 [0.51-0.96]26/26842/26830% improvement7 vitamin C COVID-19 Randomized Controlled Trialsc19vitaminc.com Sep 25, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 2.24Effect extraction pre-specifiedFavors vitamin CFavors control 00.250.50.7511.251.51.752+Zhang (RCT)50%0.50 [0.20-1.50]6/2711/29Improvement, RR [CI]TreatmentControlKumari (RCT)36%0.64 [0.26-1.55]7/7511/75JamaliMog.. (RCT)0%1.00 [0.22-4.56]3/303/30Hamidi-Ala.. (RCT)44%0.56 [0.20-1.51]5/409/40CT​1Tau​2 = 0.00; I​2 = 0.0%Late treatment41%0.59 [0.36-0.98]21/17234/17441% improvementAll studies41%0.59 [0.36-0.98]21/17234/17441% improvement4 vitamin C COVID-19 RCT mortality resultsc19vitaminc.com Sep 25, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 2.06Favors vitamin CFavors control 00.250.50.7511.251.51.752+Thomas (RCT)18%0.82 [0.53-1.27]recov. time48 (n)50 (n)CT​1Improvement, RR [CI]TreatmentControlZhao (PSM)72%0.28 [0.08-0.93]progression4/5512/55Tau​2 = 0.41; I​2 = 70.1%Early treatment46%0.54 [0.19-1.51]4/10312/10546% improvementKrishnan31%0.69 [0.47-0.92]death40/7952/73Improvement, RR [CI]TreatmentControlZhang (RCT)50%0.50 [0.20-1.50]death6/2711/29Patel29%0.71 [0.43-1.14]death22/9626/80Kumari (RCT)36%0.64 [0.26-1.55]death7/7511/75Darban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​1Gao86%0.14 [0.03-0.72]death1/465/30Hamidi-Ala.. (RCT)44%0.56 [0.20-1.51]death5/409/40CT​1Mulhem-32%1.32 [1.07-1.62]death157/794359/2,425Gadhiya-1%1.01 [0.48-1.91]death19/5536/226Hakamifard (RCT)46%0.54 [0.14-2.08]ICU3/385/34CT​1Suna21%0.79 [0.44-1.41]death17/15324/170Li (PSM)-11%1.11 [0.79-1.54]death7/819/24Vishnuram54%0.46 [0.24-0.86]death164/8,63410/241Özgünay9%0.91 [0.63-1.30]death17/3275/128Tan25%0.75 [0.10-2.98]int./death1/4614/115CT​1Tau​2 = 0.09; I​2 = 61.4%Late treatment21%0.79 [0.64-0.99]468/10,133659/3,70021% improvementBehera10%0.90 [0.63-1.21]cases29/67157/305Improvement, RR [CI]TreatmentControlLouca0%1.00 [0.97-1.04]casesTau​2 = 0.00; I​2 = 0.0%PrEP0%1.00 [0.97-1.03]29/67157/3050% improvementAll studies15%0.85 [0.74-0.98]501/10,303828/4,11015% improvement19 vitamin C COVID-19 peer reviewed trialsc19vitaminc.com Sep 25, 20211 CT: study uses combined treatmentTau​2 = 0.03; I​2 = 58.3%; Z = 2.19Effect extraction pre-specifiedFavors vitamin CFavors control 00.250.50.7511.251.51.752+Thomas (RCT)18%0.82 [0.53-1.27]recov. time48 (n)50 (n)CT​1Improvement, RR [CI]TreatmentControlZhao (PSM)72%0.28 [0.08-0.93]progression4/5512/55Zhao (PSM)-8%1.08 [0.64-1.80]viral time55 (n)55 (n)Krishnan31%0.69 [0.47-0.92]death40/7952/73Zhang (RCT)50%0.50 [0.20-1.50]death6/2711/29Zhang (RCT)80%0.20 [0.10-0.90]death5/2711/29Zhang (RCT)50%0.50 [0.20-1.80]death6/2710/29Zhang (RCT)70%0.30 [0.21-1.10]death5/2710/29Patel29%0.71 [0.43-1.14]death22/9626/80Patel16%0.84 [0.52-1.36]death15/3016/27Kumari (RCT)36%0.64 [0.26-1.55]death7/7511/75Kumari (RCT)20%0.80 [0.40-1.59]ventilation12/7515/75Kumari (RCT)26%0.74 [0.64-0.86]recov. time75 (n)75 (n)Kumari (RCT)24%0.76 [0.66-0.87]hosp. time75 (n)75 (n)Darban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​1Darban (RCT)6%0.94 [0.84-1.06]ICU10 (n)10 (n)CT​1JamaliMog.. (RCT)0%1.00 [0.22-4.56]death3/303/30JamaliMog.. (RCT)-25%1.25 [0.37-4.21]ventilation5/304/30JamaliMog.. (RCT)-31%1.31 [1.03-1.66]hosp. time30 (n)30 (n)Gao86%0.14 [0.03-0.72]death1/465/30Hamidi-Ala.. (RCT)44%0.56 [0.20-1.51]death5/409/40CT​1Hamidi-Ala.. (RCT)38%0.62 [0.45-0.86]hosp. time40 (n)40 (n)CT​1Al Sulaiman (PSM)15%0.85 [0.61-1.12]death46/14259/142Mulhem-32%1.32 [1.07-1.62]death157/794359/2,425Gadhiya-1%1.01 [0.48-1.91]death19/5536/226Hakamifard (RCT)46%0.54 [0.14-2.08]ICU3/385/34CT​1Hakamifard (RCT)1%0.99 [0.91-1.07]hosp. time38 (n)34 (n)CT​1Suna21%0.79 [0.44-1.41]death17/15324/170Suna-2%1.02 [0.46-2.24]ICU11/15312/170Li (PSM)-11%1.11 [0.79-1.54]death7/819/24Vishnuram54%0.46 [0.24-0.86]death164/8,63410/241Özgünay9%0.91 [0.63-1.30]death17/3275/128Özgünay-1%1.01 [0.79-1.29]ventilation23/3291/128Tan25%0.75 [0.10-2.98]int./death1/4614/115CT​1Tan73%0.27 [0.09-0.61]ARDS7/4641/115CT​1Behera10%0.90 [0.63-1.21]cases29/67157/305Behera17%0.83 [0.58-1.11]cases29/67157/305Louca0%1.00 [0.97-1.04]casesvitamin C COVID-19 outcomesc19vitaminc.com Sep 25, 2021Favors vitamin CFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit